Last reviewed · How we verify
Citrobacter Pneumonia — Treatment Landscape & Competitive Intelligence
4 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Fortaz | CEFTAZIDIME | Pai Holdings Pharm | ceftazidime | 1985-01-01 | ||
| Garamycin | GENTAMICIN | Merck & Co. | Aminoglycoside Antibacterial | Transient receptor potential cation channel subfamily V member 5 | 1970-01-01 | |
| Gentamicin | Gentamicin Sulfate | Merck & Co. | gentamicin | Dihydrofolate reductase | 1970-01-01 | |
| Ceftazidim | Ceftazidim | Tel-Aviv Sourasky Medical Center | Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Merck & Co. · 2 drugs in Citrobacter Pneumonia
- Pai Holdings Pharm · 2 drugs in Citrobacter Pneumonia
- · 1 drug in Citrobacter Pneumonia
- Tel-Aviv Sourasky Medical Center · 1 drug in Citrobacter Pneumonia
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Citrobacter Pneumonia:
- Citrobacter Pneumonia treatment updates — RSS
- Citrobacter Pneumonia treatment updates — Atom
- Citrobacter Pneumonia treatment updates — JSON
Cite this brief
Drug Landscape (2026). Citrobacter Pneumonia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/citrobacter-pneumonia. Accessed 2026-06-10.
Related
- Citrobacter Pneumonia full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing